与凝血因子VIII浓缩物纯度相关的免疫缺陷、艾滋病和死亡风险。多中心血友病队列研究。
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.
作者信息
Goedert J J, Cohen A R, Kessler C M, Eichinger S, Seremetis S V, Rabkin C S, Yellin F J, Rosenberg P S, Aledort L M
机构信息
AIDS and Cancer Section, Viral Epidemiology Branch, National Cancer Institute, Rockville, Maryland.
出版信息
Lancet. 1994 Sep 17;344(8925):791-2. doi: 10.1016/s0140-6736(94)92345-0.
In HIV-infected subjects with haemophilia, CD4 counts seem to fall more slowly in those on high-purity factor VIII (FVIII) than on intermediate-purity product. We evaluated whether risks for AIDS or death were associated with either product among 411 HIV-infected individuals. The relative hazard of AIDS was slightly elevated for both current (1.34) [corrected] and cumulative (1.01 per month) use of high-purity products (neither significant). The corresponding hazards for death were 1.49 and 1.03 (neither significant). Thus we found no evidence that high-purity FVIII concentrates retard the development of AIDS.
在感染人类免疫缺陷病毒（HIV）的血友病患者中，与使用中纯度产品的患者相比，使用高纯度凝血因子VIII（FVIII）的患者CD4细胞计数下降似乎更缓慢。我们评估了411名HIV感染者中使用这两种产品之一与患艾滋病或死亡风险之间的关系。当前使用（1.34）[校正后]和累积使用（每月1.01）高纯度产品时，患艾滋病的相对风险均略有升高（均无统计学意义）。相应的死亡风险分别为1.49和1.03（均无统计学意义）。因此，我们没有发现证据表明高纯度FVIII浓缩剂能延缓艾滋病的发展。
Zotero 插件